Advertisement

The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents

Maria Gavriatopoulou, Efstathios Kastritis, Ioannis Ntanasis-Stathopoulos, Despina Fotiou, Maria Roussou, Magdalini Migkou, Dimitrios C. Ziogas, Nikolaos Kanellias, Evangelos Terpos and Meletios Athanasios Dimopoulos

You do not have access to the full text of this article, the first page of the PDF of this article appears below.

PDF extract preview